Medical Professionals Reference (MPR)FDA Approves First-in-Class Treatment for Type 2 Diabetes

Mounjaro (tirzepatide) is a first-in-class, once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule. It enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. The FDA approval of Mounjaro as an adjunct therapy to diet and exercise for adults with type 2 diabetes was based on clinical trials where treatment with Mounjaro resulted in statistically significant reduction in both A1c and weight vs. semaglutide, insulin degludec, and insulin glargine.